JP Morgan Chase
BBIO icon

JP Morgan Chase’s BridgeBio Pharma BBIO Stock Holding History

JP Morgan Chase’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,200
Closed -$153K – 7733
2026
Q1 		$153K Hold
2,200
– – ﹤0.01% 5612
2025
Q4 		$168K Sell
2,200
-10,900
-83% -$715K ﹤0.01% 5623
2025
Q3 		$680K Sell
13,100
-27,200
-67% -$1.33M ﹤0.01% 4847
2025
Q2 		$1.74M Sell
40,300
-31,500
-44% -$1.15M ﹤0.01% 4017
2025
Q1 		$2.48M Buy
71,800
+21,200
+42% +$715K ﹤0.01% 3712
2024
Q4 		$1.39M Buy
+50,600
New +$1.31M ﹤0.01% 4394
2024
Q3 		– Sell
-16,100
Closed -$408K – 7410
2024
Q2 		$408K Sell
16,100
-30,800
-66% -$842K ﹤0.01% 4795
2024
Q1 		$1.45M Buy
46,900
+29,000
+162% +$986K ﹤0.01% 4080
2023
Q4 		$723K Buy
+17,900
New +$538K ﹤0.01% 4550
2023
Q3 		– Sell
-9,100
Closed -$157K – 7459
2023
Q2 		$157K Sell
9,100
-9,500
-51% -$143K ﹤0.01% 5223
2023
Q1 		$308K Buy
+18,600
New +$217K ﹤0.01% 4793
2022
Q1 		– Sell
-60,000
Closed -$1M – 6587
2021
Q4 		$1M Buy
+60,000
New +$2.54M ﹤0.01% 4380

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

JP Morgan Chase's BBIO Position: Q2 2026 in Review

JP Morgan Chase increased its BridgeBio Pharma (BBIO) stake by 83% in Q2 2026, buying an estimated $76M and bringing the position to 2,397,995 shares worth $173M. The position accounts for 0.01% of the portfolio, ranked #804.

JP Morgan Chase first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • JP Morgan Chase held 2,397,995 shares of BridgeBio Pharma worth $173M as of Q2 2026.
  • JP Morgan Chase bought 1,085,736 BridgeBio Pharma shares in Q2 2026, an estimated $76M.
  • BridgeBio Pharma made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #804 holding.
  • JP Morgan Chase first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.